Advertisement

Collagenase: Future Perspectives

  • S. Wilbrand
Chapter

Abstract

Collagenase Clostridium histolyticum (CCH) was introduced in 2009 [1] and was approved by the FDA for use in the United States under the name Xiaflex® for the treatment among adults with a palpable Dupuytren’s cord, on February 2, 2010.

References

  1. 1.
    Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med. 2009;361(10):968–97.CrossRefPubMedGoogle Scholar
  2. 2.
    Gelbard M, Goldstein I, Hellström WJ, McMahon CH, Smith T, Tursi J, Jones N, Kaufman GJ, Carson CC. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190(1):199–207.CrossRefPubMedGoogle Scholar
  3. 3.
    Coleman S, Gilpin D, Kaplan FT, Houston A, Kaufman GJ, Cohen BM, Jones N, Tursi JP. Efficacy and safety of concurrent collagenase clostridium histolyticum injections for multiple Dupuytren contractures. J Hand Surg Am. 2014;39:57–64.CrossRefPubMedGoogle Scholar
  4. 4.
    Gelbermann RH, Amiel D, Rudolph RM, et al. Dupuytren’s contracture of the Plantar fascia. J Bone Joint Surg Am. 1980;62A:425–32.CrossRefGoogle Scholar
  5. 5.
    Traore EJ, Wang W, Yafi FA, Hellstrom WJ. Collagenase Clostridium histolyticum in the management of Peyronie’s disease: a review of the evidence. Ther Adv Urol. 2016;8(3):192–202.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Veith NT, Tschernig T, Histing T, Madry H. Plantar fibromatosis--topical review. Foot Ankle Int. 2013;34(12):1742–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Hammoudeh ZS. Collagenase Clostridium histolyticum injection for plantar fibromatosis (Ledderhose disease). Plast Reconstr Surg. 2014;134(3):497e–8e.CrossRefPubMedGoogle Scholar
  8. 8.
    Luck V. Dupuytren’s contracture. A new concept of the pathogenesis correlated with surgical management. J Bone Joint Surg. 1959;41:635–64.CrossRefPubMedGoogle Scholar
  9. 9.
    Meek RMD, McClellan S, Reilly J, et al. The effect of steroids on Dupuytren’s disease: role of programmed cell death. J Hand Surg. 2002;27:270–3.CrossRefGoogle Scholar
  10. 10.
    Ketchum LD, Donahue TK. The injection of nodules of Dupuytren’s disease with triamcinolone acetonide. J Hand Surg. 2000;25A:1157–62.CrossRefGoogle Scholar
  11. 11.
    Manske RC, Prohaska D. Diagnosis and management of adhesive capsulitis. Curr Rev Musculoskelet Med. 2008;1(3-4):180–9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Bulgen DY, Binder A, Hazeman BL, et al. Immunological studies in frozen shoulder. J Rheumatol. 1992;9(6):893–8.Google Scholar
  13. 13.
    Badalamente MA, Wang ED. CORR®ORS Richard A. Brand award: clinical trials of a new treatment method for adhesive capsulitis. Clin Orthop Relat Res. 2016;474(11):2327–36.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Tamboto H, Vicjery K, Deva AK. Subclinical (biofilm) infection causes capsular contracture in a porcine model following augmentation mammoplasty. Plast Reconstr Surg. 2010;126(3):835–42.CrossRefPubMedGoogle Scholar
  15. 15.
    Fischer S, Hirche C, Diehm Y, Nuutila K, Kiefer J, Gazyakan E, Bueno EM, Kremer T, Kneser U, Pomahac B. Efficacy and safety of the collagenase of the Bacterium Clostridium histolyticum for the treatment of capsular contracture after silicone implants: ex-vivo study on human tissue. PLoS One. 2016;11(5):e0156428.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kang N, Sivakumar B, Sanders R, Nduka C, Gault D. Intra-lesional injections of collagenase are ineffective in the treatment of keloid and hypertrophic scars. J Plast Reconstr Aesthet Surg. 2006;59(7):693–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Bae-Harboe YS, Harboe-Schmidt JE, Graber E, Gilchrest BA. Collagenase followed by compression for the treatment of earlobe keloids. Dermatol Surg. 2014;40(5):519–24.CrossRefPubMedGoogle Scholar
  18. 18.
    Auxilium Pharmaceuticals, Inc. Press Release. “Auxilium Pharmaceuticals, Inc. announces positive data from phase 2a study of CCH in patients with cellulite.” August 21, 2014.Google Scholar
  19. 19.
    BioSpecifics Technologies Corp. Press Release. BioSpecifics Technologies Corp. announced positive, highly statistically significant results from a Phase 2b study of CCH for the treatment of cellulite, or edematous fibrosclerotic panniculopathy. Lynbrook, NY, November 17, 2016.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Hand SurgeryUppsala University HospitalUppsalaSweden

Personalised recommendations